Travere Therapeutics reported earnings of -$ 0.55 per TVTX share on Nov 2, 2026, beating analysts' expectations by
| Report Date | Nov 2, 2026 |
|---|---|
| Forecasted EPS | -$ 0.06 |
| Earnings Per Share (Surprise) | -$ 0.55 (-$ 0.49) |
| Last Year's EPS | -$ 0.07 |
| EPS YoY Change |
Out of the last 65 earnings reporting periods, Travere Therapeutics beat analysts’ expectations 15 times and fell short of expectations 33 time(s). Travere Therapeutics reported earnings per share of -$ 0.55 in the last report falling to reach an estimated EPS of -$ 0.06 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 2, 2026 | -$ 0.06 | -$ 0.55 | $ 0.28 | |
| Aug 4, 2026 | -$ 0.13 | -$ 0.37 | -$ 0.14 | |
| May 4, 2026 | -$ 0.30 | -$ 0.39 | -$ 0.47 | |
| Feb 19, 2026 | $ 0.03 | $ 0.03 | -$ 0.73 | |
| Oct 30, 2025 | -$ 0.31 | $ 0.28 | -$ 0.70 | |
| Aug 6, 2025 | -$ 0.28 | -$ 0.14 | -$ 0.90 | |
| May 1, 2025 | -$ 0.55 | -$ 0.47 | -$ 1.76 | |
| Feb 20, 2025 | -$ 0.58 | -$ 0.73 | -$ 1.16 | |
| Oct 31, 2024 | -$ 0.70 | -$ 0.70 | -$ 1.17 | |
| Aug 1, 2024 | -$ 0.87 | -$ 0.90 | -$ 1.13 | |
| May 6, 2024 | -$ 0.98 | -$ 1.76 | -$ 1.27 | |
| Feb 15, 2024 | -$ 1.27 | -$ 1.16 | -$ 1.03 | |
| Nov 7, 2023 | -$ 1.09 | -$ 1.17 | -$ 1.09 | |
| Aug 3, 2023 | -$ 1.16 | -$ 1.13 | -$ 1.05 | |
| May 4, 2023 | -$ 1.18 | -$ 1.27 | -$ 1.20 | |
| Feb 23, 2023 | -$ 1.04 | -$ 1.03 | -$ 0.84 | |
| Oct 27, 2022 | -$ 0.97 | -$ 1.09 | -$ 0.59 | |
| Aug 4, 2022 | -$ 0.94 | -$ 1.05 | -$ 0.64 | |
| May 5, 2022 | -$ 0.85 | -$ 1.20 | -$ 0.96 | |
| Feb 24, 2022 | -$ 0.72 | -$ 0.84 | -$ 2.37 |
Travere Therapeutics’s stock was trading at $ 50.39 on Nov 1, 2026 a day before the last earnings report was released.Following the release of the earnings report, TVTX’s price decreased to $ 49.41 on Nov 3, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 2, 2026 | -$ 0.55 | $ 50.39 | $ 49.41 | |
| Aug 4, 2026 | -$ 0.37 | $ 54.98 | $ 62.76 | |
| May 4, 2026 | -$ 0.39 | $ 44.12 | $ 44.80 | |
| Feb 19, 2026 | $ 0.03 | $ 27.87 | $ 30.39 | |
| Oct 30, 2025 | $ 0.28 | $ 29.98 | $ 35.16 | |
| Aug 6, 2025 | -$ 0.14 | $ 16.68 | $ 16.91 | |
| May 1, 2025 | -$ 0.47 | $ 20.81 | $ 21.15 | |
| Feb 20, 2025 | -$ 0.73 | $ 23.33 | $ 21.98 | |
| Oct 31, 2024 | -$ 0.70 | $ 17.76 | $ 17.57 | |
| Aug 1, 2024 | -$ 0.90 | $ 9.54 | $ 9.00 | |
| May 6, 2024 | -$ 1.76 | $ 6.26 | $ 6.75 | |
| Feb 15, 2024 | -$ 1.16 | $ 8.25 | $ 8.20 | |
| Nov 7, 2023 | -$ 1.17 | $ 6.64 | $ 6.33 | |
| Aug 3, 2023 | -$ 1.13 | $ 16.62 | $ 15.52 | |
| May 4, 2023 | -$ 1.27 | $ 15.91 | $ 16.80 | |
| Feb 23, 2023 | -$ 1.03 | $ 20.87 | $ 22.30 | |
| Oct 27, 2022 | -$ 1.09 | $ 22.24 | $ 22.94 | |
| Aug 4, 2022 | -$ 1.05 | $ 24.00 | $ 27.83 | |
| May 5, 2022 | -$ 1.20 | $ 25.91 | $ 22.24 | |
| Feb 24, 2022 | -$ 0.84 | $ 26.09 | $ 26.85 |
Travere Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Travere Therapeutics missed analysts’ expectations during the last earnings period by
